丰原药业：2025年半年度净利润约7628万元

Core Viewpoint - Fengyuan Pharmaceutical reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 2.027 billion yuan, a year-on-year decrease of 12.16% [2] - The net profit attributable to shareholders was around 76.28 million yuan, reflecting a year-on-year decline of 23.88% [2] - Basic earnings per share were reported at 0.1641 yuan, down 23.89% compared to the previous year [2]